Skip to main content

Newsroom

Latest News

June 26, 2024

DENVER, CO — Today, Congresswoman Diana DeGette (CO-01) announced that the City and County of Denver is receiving a $4.5 million grant from the Department of Housing and Urban Development.

June 23, 2024

DENVER, CO – Today, Congresswoman Diana DeGette (D-CO), co-chair of the House Pro-Choice Caucus, released the following statement ahead of the second anniversary of the Dobbs v. Jackson Women's Health Organization ruling.

June 18, 2024

DENVER, CO — Today, Congresswoman Diana DeGette (CO-01) released the following statement after the Senate passed S. 870, legislation that includes the bill written by Rep.

June 14, 2024

WASHINGTON D.C. — Today, Congresswoman Diana DeGette (CO-01) released the following statement after the Supreme Court struck down a ban of bump stocks.

June 6, 2024

WASHINGTON, D.C. — Today, Congresswoman Diana DeGette (CO-01) and Congressman Larry Bucshon, M.D. (IN-08) sent a letter to stakeholders, interest groups, and health care advocates requesting information on what Congress can do to bring about the next generation of treatments. 

May 30, 2024

DENVER, CO — Today, Congresswoman Diana DeGette (CO-01), a former trial attorney, released the following statement after former President Donald Trump was found guilty on 34 felony counts of falsifying business records.

May 9, 2024

DENVER, CO –  Today, Congresswoman Diana DeGette (CO-01) announced that six organizations throughout Denver will receive $15,199,419in grants and education awards from Ame

May 9, 2024

WASHINGTON, D.C. — Today, Congresswoman Diana DeGette (CO-01) released the following statement after voting against the procedural vote that preceded the motion to vacate the chair.

May 2, 2024

WASHINGTON D.C. — Today, Congresswoman Diana DeGette (CO-01) released the following statement after voting against H.R. 6090.

April 29, 2024

WASHINGTON D.C. — Today, Congresswoman Diana DeGette (CO-01) and Congressman Larry Bucshon, M.D. (IN-08) released the following statement after the Food and Drug Administration (FDA) finalized a rule regulating lab-developed tests (LDTs), a subset of in-vitro clinical tests (IVCTs).